Idioma:

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study

Chasnyk, Vyacheslav ; Palmblad, Karin ; I. Brunner, Hermine ; Marzan, Katherine ; Schneider, Rayfel ; Horneff, Gerd ; Martini, Alberto ; Anton, Jordi ; Wei, Xiaoling ; Ruperto, Nicolino ; Abrams, Ken ; Ulbrich, A. ; Fodor, S. ; Lauwerys, B. ; Brichard, B. ; Knupp Feitosa, S. ; Felix Rodrigues, M. ; Mattei de, L. ; Kozu, K. ; Laxer, Ronald ; Houghton, K. ; Mogenet, A. ; Bader Meunier, B. ; Meyzer, C. ; Semeraro, M. ; Ben‐Brahim, O. ; Kone‐Paut, I. ; Galeotti, C. ; Dusser, P. ; Duquesne, A. ; Desjonqueres, M. ; Foeldvari, I. ; Kienast, A. ; Geikowski, T. ; Schulz, A. ; Hirdes, M. ; Janda, A. ; Jacob, A. ; Emerich, C. ; Raab, A. ; Minden, K. ; Lieber, M. ; Haselbusch, D. ; Kolbeck, H. ; Kuemmerle Deschner, J. ; Hansmann, S. ; Schleich, T. ; Magunia, I. ; Anders, N. ; Helling‐Bakki, A. ; Garan, D. ; Orban, I. ; Butbul, Y. ; Helo, M. ; Uziel, Y. ; Haviv, R. ; Moshe, V. ; Rothschild, M. ; Harel, L. ; Amarilyo, G. ; Said, M. ; Gerstein, M. ; Ravelli, A. ; Schiappapietra, B. ; Varnier, G. ; Finetti, M. ; Caorsi, R. ; Pontikaki, I. ; Gerloni, V. ; Ubiali, T. ; Vastert, S. ; Szczygielska, I. ; Kwiatkowska, M. ; Snegireva, L. ; Kostik, M. ; Kalashnikova, O. ; Galindo Zavala, R. ; Iglesias, E. ; Calzada, J. ; Gamir, M. L. ; Merino, R. ; Alcobendas, R. ; Remesal, A. ; Calvo, I. ; Gonzalez, I. ; Barut, K. ; Adrovic, A. ; Sahin, S. ; Gozdenur Savci, R. ; Demir, S. ; Bilginer, Y. ; Batu, E. D. ; Reiff, Andreas ; Brown, Diana ; Shaham, Bracha ; Higgins, G. ; Spencer, C. ; Jones, K. ; Farley, S. ; Akoghlanian, S.

Arthritis & rheumatology (Hoboken, N.J.), 2021-02, Vol.73 (2), p.336-346 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
Autor: Chasnyk, Vyacheslav ; Palmblad, Karin ; I. Brunner, Hermine ; Marzan, Katherine ; Schneider, Rayfel ; Horneff, Gerd ; Martini, Alberto ; Anton, Jordi ; Wei, Xiaoling ; Ruperto, Nicolino ; Abrams, Ken ; Ulbrich, A. ; Fodor, S. ; Lauwerys, B. ; Brichard, B. ; Knupp Feitosa, S. ; Felix Rodrigues, M. ; Mattei de, L. ; Kozu, K. ; Laxer, Ronald ; Houghton, K. ; Mogenet, A. ; Bader Meunier, B. ; Meyzer, C. ; Semeraro, M. ; Ben‐Brahim, O. ; Kone‐Paut, I. ; Galeotti, C. ; Dusser, P. ; Duquesne, A. ; Desjonqueres, M. ; Foeldvari, I. ; Kienast, A. ; Geikowski, T. ; Schulz, A. ; Hirdes, M. ; Janda, A. ; Jacob, A. ; Emerich, C. ; Raab, A. ; Minden, K. ; Lieber, M. ; Haselbusch, D. ; Kolbeck, H. ; Kuemmerle Deschner, J. ; Hansmann, S. ; Schleich, T. ; Magunia, I. ; Anders, N. ; Helling‐Bakki, A. ; Garan, D. ; Orban, I. ; Butbul, Y. ; Helo, M. ; Uziel, Y. ; Haviv, R. ; Moshe, V. ; Rothschild, M. ; Harel, L. ; Amarilyo, G. ; Said, M. ; Gerstein, M. ; Ravelli, A. ; Schiappapietra, B. ; Varnier, G. ; Finetti, M. ; Caorsi, R. ; Pontikaki, I. ; Gerloni, V. ; Ubiali, T. ; Vastert, S. ; Szczygielska, I. ; Kwiatkowska, M. ; Snegireva, L. ; Kostik, M. ; Kalashnikova, O. ; Galindo Zavala, R. ; Iglesias, E. ; Calzada, J. ; Gamir, M. L. ; Merino, R. ; Alcobendas, R. ; Remesal, A. ; Calvo, I. ; Gonzalez, I. ; Barut, K. ; Adrovic, A. ; Sahin, S. ; Gozdenur Savci, R. ; Demir, S. ; Bilginer, Y. ; Batu, E. D. ; Reiff, Andreas ; Brown, Diana ; Shaham, Bracha ; Higgins, G. ; Spencer, C. ; Jones, K. ; Farley, S. ; Akoghlanian, S.
Assuntos: Adolescent ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Juvenile - drug therapy ; Arthritis, Juvenile - physiopathology ; Child ; Child, Preschool ; Deprescriptions ; Drug Tapering - methods ; Exposure ; Female ; Full Length ; Glucocorticoids ; Glucocorticoids - therapeutic use ; Humans ; Interleukins ; Male ; Medicin och hälsovetenskap ; Methotrexate ; Methotrexate - therapeutic use ; Monoclonal antibodies ; Patients ; Pediatric Rheumatology ; Remission ; Remission (Medicine) ; Remission Induction ; Safety ; Tapering ; Toxicity
É parte de: Arthritis & rheumatology (Hoboken, N.J.), 2021-02, Vol.73 (2), p.336-346
Notas: Supported by Novartis Pharma AG.
ClinicalTrials.gov identifier: NCT02296424.
Dr. Quartier has received consulting fees, speaking fees, and/or honoraria from Novartis (less than $10,000). Dr. Brunner has received consulting fees, speaking fees, and/or honoraria from GlaxoSmithKline (less than $10,000) and from Roche and Novartis (more than $10,000 each). Dr. Schneider has received consulting fees from Novartis, NovImmune, Sobi, and Roche (less than $10,000 each). Dr. Horneff has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, GSK, Novartis, Pfizer, and Sobi (less than $10,000 each). Dr. Martini has received consulting fees, speaking fees, and or honoraria from Eli Lilly, EMD Serono, Janssen, Novartis, Pfizer, and AbbVie (less than $10,000 each). Dr. Anton has received consulting fees, speaking fees, and/or honoraria from Novartis, Sobi, Roche, Sanofi, AbbVie, Pfizer, and NovImmune (less than $10,000 each). Dr. Wei owns stock or stock options in Novartis. Dr. Ruperto has received consulting fees from Ablynx, AbbVie, AstraZeneca‐Medimmune, Biogen, Boehringer, Bristol Myers Squibb, Eli Lilly, EMD Serono, GlaxoSmithKline, Hoffmann‐La Roche, Janssen, Merck, Novartis, Pfizer, R‐Pharma, Sanofi, Servier, Sinergie, Sobi, and Takeda (less than $10,000 each). No other disclosures relevant to this article were reported.
Descrição: Objective To evaluate the efficacy and safety of 2 canakinumab monotherapy tapering regimens in order to maintain complete clinical remission in children with systemic juvenile idiopathic arthritis (JIA). Methods The study was designed as a 2‐part phase IIIb/IV open‐label, randomized trial. In the first part, patients received 4 mg/kg of canakinumab subcutaneously every 4 weeks and discontinued glucocorticoids and/or methotrexate as appropriate. Patients in whom clinical remission was achieved (inactive disease for at least 24 weeks) with canakinumab monotherapy were entered into the second part of the trial, in which they were randomized 1:1 into 1 of 2 treatment arms. In arm 1, the dose of canakinumab was reduced from 4 mg/kg to 2 mg/kg and then to 1 mg/kg, followed by discontinuation. In arm 2, the 4 mg/kg dose interval was prolonged from every 4 weeks, to every 8 weeks, and then to every 12 weeks, followed by discontinuation. In both arms, canakinumab exposure could be reduced provided systemic JIA remained in clinical remission for 24 weeks with each step. The primary objective was to assess whether >40% of randomized patients in either arm maintained clinical remission of systemic JIA for 24 weeks in the first part of the study. Results In part 1 of the study, 182 patients were enrolled, with 75 of those patients randomized before entering part 2 of the trial. Among the 75 randomized patients, clinical remission was maintained for 24 weeks in 27 (71%) of 38 patients in arm 1 (2 mg/kg every 4 weeks) and 31 (84%) of 37 patients in arm 2 (4 mg/kg every 8 weeks) (P ≤ 0.0001 for arm 1 versus arm 2 among those meeting the 40% threshold). Overall, 25 (33%) of 75 patients discontinued canakinumab, and clinical remission was maintained for at least 24 weeks in all 25 of these patients. No new safety signals were identified. Conclusion Reduction of canakinumab exposure may be feasible in patients who have achieved clinical remission of systemic JIA, but consistent interleukin‐1 inhibition appears necessary to maintain this response.
Editor: United States: Wiley Subscription Services, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 4 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study

United States: Wiley Subscription Services, Inc

Buscando em bases de dados remotas. Favor aguardar.